S

    Spero Therapeutics Inc (SPRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.20
    -0.01 (-0.83%)

    Market Cap: $69.88M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(25/35)
    Avg Surprise
    +87.32%
    Streak
    6 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.16$-0.19+15.79%Beat-433.3%
    Mar 26
    		$-0.13$-0.18+30.17%Beat+49.7%
    Dec 25
    		$0.53$-0.20+365.45%Beat+244.7%
    Sep 25
    		$-0.13$-0.25+48.00%Beat+59.4%
    Jun 25
    		$-0.03N/A+92.11%Beat+90.9%
    Mar 25
    		$-0.25$-0.44+43.18%Beat-4.2%
    Dec 24
    		$-0.37$-0.31-18.35%Miss-138.2%
    Sep 24
    		$-0.32$-0.36+11.11%Beat-900.0%
    Jun 24
    		$-0.33$-0.38+13.16%Beat-43.5%
    Mar 24
    		$-0.24$-0.06-300.00%Miss+4.0%
    Dec 23
    		$0.96$-0.10+1060.00%Beat+74.5%
    Sep 23
    		$0.04$-0.03+233.33%Beat+112.1%
    Jun 23
    		$-0.23$-0.37+37.84%Beat+46.5%
    Mar 23
    		$-0.25$-0.26+3.85%Beat+75.2%
    Dec 22
    		$0.55$0.04+1275.00%Beat+161.1%
    Sep 22
    		$-0.33$-0.24-37.50%Miss+52.9%
    Jun 22
    		$-0.43N/A+53.76%Beat+31.7%
    Mar 22
    		$-1.01$-0.95-6.32%Miss-53.0%
    Dec 21
    		$-0.90$-0.75-20.00%Miss-32.4%
    Sep 21
    		$-0.70$-0.66-6.06%Miss+18.6%
    Jun 21
    		$-0.63$-0.75+16.00%Beat+25.9%
    Mar 21
    		$-0.66$-0.63-4.76%Miss+44.5%
    Dec 20
    		$-0.68$-0.74+8.11%Beat+50.0%
    Sep 20
    		$-0.86$-0.89+3.37%Beat+9.5%
    Jun 20
    		$-0.85$-1.13+24.78%Beat-14.9%
    Mar 20
    		$-1.19$-1.25+4.80%Beat-310.3%
    Dec 19
    		$-1.36$-1.08-25.93%Miss-126.7%
    Sep 19
    		$-0.95$-0.85-11.76%Miss-58.3%
    Jun 19
    		$-0.74$-0.86+13.95%Beat-7.2%
    Mar 19
    		$-0.29N/A+62.34%Beat+60.8%
    Dec 18
    		$-0.60$-0.75+20.00%Beat+98.3%
    Sep 18
    		$-0.60$-0.63+4.76%Beat+79.7%
    Jun 18
    		$-0.69$-0.77+10.39%Beat-35.3%
    Mar 18
    		$-0.74$-1.20+38.33%Beat-
    Sep 17
    		$-36.02$-35.07-2.71%Miss-
    Jun 17
    		$-2.96$0.00N/AMiss-
    Mar 17
    		$-0.51$0.00N/AMiss-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.
    View SPRO's full dividend history

    Key Metrics

    Valuation
    P/E Ratio10.42EV/EBITDA3.29x
    Price/FCF3.55xFCF Yield28.15%
    Profitability
    Profit Margin15.70%Operating Margin14.10%
    ROE19.20%ROIC10.74%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.12xQuick Ratio6.12x
    Trading Statistics
    Beta1.48Avg Volume598.48K
    52-Week High$3.0852-Week Low$1.08

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.21
    SMA 20$1.22
    SMA 50$1.56
    SMA 200$2.25
    EMA 10$1.22
    EMA 20$1.26
    EMA 50$1.55
    EMA 200$2.03

    MACD

    Line: -0.09Signal: -0.12Hist: 0.03

    ADX

    ADX: 38.0+DI: 14.0-DI: 23.4

    Aroon & PSAR

    Aroon Up56.0
    Aroon DownN/A
    PSAR$1.29

    Bollinger Bands

    Upper Band$1.28
    Lower Band$1.17
    %B Position903%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    34.5

    Momentum Oscillators

    Stoch %K28.0
    Stoch %D33.8
    Williams %R-80.0
    ROC (10d)-2.4%
    Momentum-0.03
    CCI (20d)-81.2
    MFI (14d)40.9

    Volatility Measures

    ATR (14d)$0.07(6.0%)
    StdDev (20d)0.03
    Hist Vol39.4%(Moderate)

    Volume Flow

    VWAP$1.20
    OBV198.2M
    AD Line47.4M
    CMF (20d)-0.042

    Volume Metrics

    Avg Vol (20d)592.7K
    Vol Ratio0.5x
    VWMA (20d)$1.22

    Pivot Points

    R3$1.28
    R2$1.26
    R1$1.23
    Pivot Point$1.21
    S1$1.18
    S2$1.16
    S3$1.13

    Advanced Oscillators

    TSI-33.65
    Ultimate Osc41.9
    KST-162.79

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$258,000$41.30M$5.44M$14.19M$5.87M$15.04M$13.47M$10.20M$9.27M$73.52M$25.47M
    Cost of Revenue$0$0N/A$0$0$0$94.63M$0$0$0$49.43M$0
    Gross Profit$0$258,000$41.30M$5.44M$14.19M$5.87M$15.04M$13.47M$10.20M$9.27M$73.52M$25.47M
    Operating Expenses$9.93M$7.80M$9.89M$13.36M$16.63M$20.61M$36.77M$32.06M$29.26M$23.25M$22.99M$27.41M
    R&D$3.43M$2.91M$5.59M$8.60M$10.67M$13.61M$28.84M$26.86M$23.73M$17.33M$16.56M$16.39M
    SG&A$6.49M$4.89M$4.30M$4.17M$5.88M$6.82M$7.06M$5.20M$5.53M$5.92M$6.43M$5.71M
    Operating Income$-9,926,000$-7,538,000$31.41M$-7,916,000$-2,444,000$-14,731,000$-21,725,000$-18,593,000$-19,061,000$-13,982,000$50.53M$-1,934,000
    Interest Income$377,000$336,000$376,000$532,000$740,000$864,000$1.03M$1.18M$1.20M$1.33M$1.04M$950,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-9,552,000$-7,203,000$31.78M$-7,382,000$-1,700,000$-13,866,000$-20,598,000$-17,437,000$-17,862,000$-12,669,000$51.58M$-994,000
    Income Tax Expense$0$0$0$0$0$0$0$290,000$0$0$387,000$2.21M
    Net Income$-9,552,000$-7,203,000$31.52M$-7,382,000$-1,700,000$-13,866,000$-20,888,000$-17,147,000$-17,862,000$-12,669,000$51.19M$-3,205,000
    EBITDA$-9,929,000$-7,539,000$31.41M$-7,914,000$-2,440,000$-14,730,000$-21,626,000$-18,619,000$-19,058,000$-13,996,000$50.57M$-1,836,000
    EBIT$-9,929,000$-7,539,000$31.41M$-7,914,000$-2,440,000$-14,730,000$-21,626,000$-18,619,000$-19,060,000$-13,996,000$50.54M$-1,944,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SPRO

    Government Contracts

    Gov Obligations (TTM)
    -$599066
    Gov Obligations / Revenue
    -1.0%
    Obligations YoY
    -106.1%
    Active Awards
    2
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Spero Therapeutics Inc (MEX:SPRO) Stock Holders - Institutional & Insider Ownership

    This article provides an overview of Spero Therapeutics Inc.'s (MEX:SPRO) institutional and insider ownership. It details the percentage of shares held by institutions and insiders, along with historical trends, and offers key financial metrics for the company. The article also notes warning signs detected by GuruFocus for SPRO.

    GuruFocus•8/22/26•
    Neutral

    Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

    Spero Therapeutics reported zero revenue for Q2 2026, a net loss of $9.6 million, and a diluted net loss per share of $0.16. Following FDA approval of Utebzi and a $105 million nonrecourse financing, the company is pivoting to immune-mediated diseases, in-licensing SP001 for IgG4-related disease with a Phase II trial expected to start in Q2 2027. Management believes current capital will fund operating expenses into the second half of 2029.

    The Globe and Mail•8/20/26•
    Somewhat-Bullish

    Net current asset value per share of Spero Therapeutics, Inc. – BMV:SPRO

    This page displays information about the net current asset value per share of Spero Therapeutics, Inc. (BMV:SPRO). It is part of the financial data provided by TradingView for the Mexican Stock Exchange, indicating market status and historical values.

    TradingView•8/16/26•
    Neutral

    Long term debt to total assets ratio of Spero Therapeutics, Inc. – BMV:SPRO

    This article focuses on the long-term debt to total assets ratio for Spero Therapeutics, Inc. (BMV:SPRO). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics. The main content indicates the specific financial ratio being presented.

    TradingView•8/15/26•
    Neutral

    Spero Therapeutics 2Q 2026: Revenue $0M, EPS $(0.16) — 10-Q Summary

    Spero Therapeutics reported its second quarter 2026 results, showing $0M in revenue and a diluted EPS of $(0.16), a significant decrease from the prior year. Key business updates include the FDA approval of Utebzi, the in-license and development of SP001, and a $105M non-dilutive royalty financing that extends liquidity into H2 2029. The company also realigned operational costs following trial completions and program terminations.

    TradingView•8/12/26•
    Neutral

    Frequently Asked Questions About SPRO

    Does SPRO pay dividends?
    Spero Therapeutics Inc (SPRO) has a dividend payment track record. See the SPRO dividend history page for its current payment status, yield, and streaks.
    What is SPRO's P/E ratio?
    Spero Therapeutics Inc has a price-to-earnings (P/E) ratio of 10.42.
    What is SPRO's market cap?
    Spero Therapeutics Inc (SPRO) has a market capitalization of $69.88M with a current stock price of $1.20.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In